PMC Group and The Chakrabarti Foundation Make Donation to Ramakrishna Mission Saradapitha Belur Math of West Bengal
14.3.2023 12:45:00 EET | Business Wire | Press release
Paritosh M. Chakrabarti, business owner, author and philanthropist, today announced PMC Group and The Chakrabarti Foundation have made a sizeable donation of land and property to the Ramakrishna Mission Saradapitha Belur Math of West Bengal.
“Contributing to the Ramakrishna Mission Saradapitha is an honor. The Mission enshrines the teachings of India’s greatest spiritual leader and unifier of humanity, Swami Vivekananda,” explained Paritosh Chakrabarti. “This gift is a way for me to further those ideals. I am appreciative to Belur Math for accepting the donation. These gifts are also part of the ‘soul’ of PMC Group that I describe in my upcoming book, The Makings of PMC Group – A Corporation with a Soul."
The donation includes the notable Bose House which has been witness to many historical events and carries memories of great patriots and revolutionaries, the surrounding land, and a significant financial gift. The financial gift will provide for 1.) construction and development of two museum rooms, each housing panel exhibition-cum-photo galleries, manuscripts, rare and valuable collections and potentially, a multimedia presentation depicting the lives, activities, and legacies of Swami Vivekananda and Netaji Subhas Chandra Bose, 2.) production of cultural and educational activities to promote inter-cultural and inter-religious harmony and, 3.) installation of a commemorative plaque stating: “This historic Bose House Property has been donated by Paritosh M. Chakrabarti and Srimati Chakrabarti to Ramakrishna Mission Saradapitha, Belur Math for the Construction and Development of a Cultural and Educational Center to Promote the legacy of Swamiji and Netaji”.
The chairman of Rishra Municipality, Vijay Sagar Mishra said, “It’s a matter of great joy and honor for all of us to watch the handing over ceremony of Rishra Bose House to Ramakrishna Mission Saradapitha Belur Math. Converting it to a museum will bring the common people closer to the works and activities of the great patriot Netaji Subhas Chandra Bose and Swami Vivekananda. The present generation must be made aware of the glorious history so that they can take lessons from it and go ahead in serving the motherland.”
ABOUT PMC
PMC Group, owned by Paritosh M. Chakrabarti and his family, is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com.
ABOUT THE CHAKRABARTI FOUNDATION
The Chakrabarti Foundation is a non-profit organization dedicated to promoting education around the world and believes excellence in education is a primary requirement for enduring civilization. To learn more please visit https://pmc-group.com/chakrabarti-foundation.
ABOUT RAMAKRISHNA MISSION SARADAPITHA BELUR MATH
Ramakrishna Mission Saradapitha Belur Math is a well-known and reputed philanthropic organization serving the society of India and abroad irrespective of caste, color, creed, religion, nationality, gender, regional bias, etc., through its vast network of nearly more than 250 branch-centers in the fields of education, culture, religion, health, relief and rehabilitation, rural and tribal development, publications, teachings and preaching and a large number of allied areas all of which are for the all-around development of the individual and the society as a whole. More can be found at https://belurmath.org/ramakrishna-mission-saradapitha-belur.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005278/en/
Contact information
Patti Griggs 856-533-1870
pgriggs@pmc-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 09:00:00 EEST | Press release
Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to digital to manage their businesses. In late 2025, Tide received a strategic investment from TPG, a leading global alternative asset manager, valuing the company at $1.5 billion. Oliver Prill, CEO of Tide, said: “We are delighted to be crossing the 2 million member milestone. This number is a testament to the trust that our members place in us in all our markets. Behind every
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom